We provide you with 20 years of free, institutional-grade data for AYLA stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of AYLA. Explore the full financial landscape of AYLA stock.
| Reported Date | CIK | Ticker | Type |
|---|
Ayala Pharmaceuticals, Inc(NASDAQ:AYLA) 
Ayala Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, which is an intravenous injectable small molecule gam...
Website: http://www.ayalapharma.com
Founded: 2017
Full Time Employees: 34 (May 2021)
CEO: Roni Mamluk
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report about AYLA stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.